Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Regeneron Pharmaceuticals has declined to submit a new bid exceeding its original $256 million offer for 23andMe, paving the way for co-founder Anne Wojcicki to regain control of the DNA-testing company with a $305 million bid from a nonprofit she controls. 23andMe filed for bankruptcy in March after a decline in demand and a 2023 data breach, and Wojcicki's bid is expected to close in the coming weeks following a court hearing on June 17.

Analysis

Regeneron Pharmaceuticals (REGN) has elected not to increase its $256 million bid for the bankrupt genetic testing company 23andMe, effectively ceding the acquisition to a $305 million offer from TTAM Research Institute, a nonprofit controlled by 23andMe co-founder Anne Wojcicki. This development resolves the auction for 23andMe, which sought bankruptcy protection in March following a decline in consumer demand and a significant 2023 data breach that exposed sensitive information of millions of customers. Regeneron's decision to withdraw, despite previously indicating potential interest in a revised bid contingent on a $10 million breakup fee, signals a disciplined capital allocation strategy. The company reiterated its commitment to its internal genetics research capabilities, including the Regeneron Genetics Center and Regeneron Genetic Medicines, suggesting the pursuit of 23andMe was an opportunistic rather than a core strategic necessity. The neutral per-ticker sentiment (0.0 for REGN) aligns with this interpretation, indicating the market does not view Regeneron's withdrawal as materially impacting its fundamental prospects. Wojcicki's successful bid is anticipated to close following a court hearing on June 17, with TTAM Research Institute pledging to uphold 23andMe's existing privacy policies.

Key Decisions for Investors

• For Regeneron investors, this outcome underscores the company's financial discipline regarding M&A and reinforces its primary strategic focus on organic growth through its established genetics research programs.
• Investors should maintain their focus on Regeneron's pipeline developments and internal R&D progress, as these remain the principal drivers of shareholder value, rather than the outcome of this relatively minor, unsuccessful acquisition attempt.
• This event suggests Regeneron will likely continue to adopt an opportunistic and value-conscious approach to future M&A, prioritizing strategic fit and financial prudence over aggressive bidding for non-core assets.